Kayla Wardle 9/30/25 Kayla Wardle 9/30/25 POIESIS This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Read More
Kayla Wardle 9/30/25 Kayla Wardle 9/30/25 POIESIS This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Read More
